Isatuximab

Isatuximab is a monoclonal antibody (mAb) designed for the treatment of cancer. It was developed by ImmunoGen and Sanofi-Aventis with the development name SAR-650984. It was given orphan drug status for multiple myeloma by the FDA in December 2016.

Contents

• Isatuximab for multiple myeloma promising results and next steps
• Overview of a phase ii clinical trial of isatuximab
• References

Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. As of 2015, it is in phase II trials for multiple myeloma and T-cell leukemia.

A phase III combination trial for plasma cell myeloma is comparing pomalidomide and dexamethasone with and without isatuximab is in progress with an estimated completion date of 2021.